← Back to Clinical Trials
Recruiting NCT06736951

NCT06736951 Modifying the Inpatient Environment to Reduce Delirium in Older Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06736951
Status Recruiting
Phase
Sponsor Farhaan S. Vahidy
Condition Delirium
Study Type INTERVENTIONAL
Enrollment 10,890 participants
Start Date 2024-06-01
Primary Completion 2029-03-31

Eligibility & Interventions

Sex All sexes
Min Age 70 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
MMSH (Multi-Modal Sleep Hygiene) Bundle

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 10,890 participants in total. It began in 2024-06-01 with a primary completion date of 2029-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall goal is to reduce the incidence and burden of delirium, as measured by the delirium burden index (DBI) among hospitalized older adults (≥70 years), by modifying the inpatient environment to decrease its sleep antagonism. The investigators propose to implement a multi-modal sleep hygiene (MMSH) bundle, an enhancement of a previously reported sleep-focused intervention which had 88 - 100% compliance for intervention components, and reduced ICU delirium by 50%.

Eligibility Criteria

Inclusion criteria: * Non-critically ill patients (≥70 years) * All sexes * All races and ethnicities * Admitted to the pre-specified clinical units which are part of the study Exclusion criteria (applied during analysis): * Patients with active alcohol or substance withdrawal. * Patients with acute psychiatric illness * Patients with initial admission to intensive care unit including requirement for mechanical ventilation. * Patients present on a unit at the time of unit randomization

Contact & Investigator

Central Contact

Rejani Nair, BSN

✉ rrnair@houstonmethodist.org

📞 346-356-1496

Principal Investigator

Farhaan Vahidy, PhD

PRINCIPAL INVESTIGATOR

The Methodist Hospital Research Institute

Frequently Asked Questions

Who can join the NCT06736951 clinical trial?

This trial is open to participants of all sexes, aged 70 Years or older, studying Delirium. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06736951 currently recruiting?

Yes, NCT06736951 is actively recruiting participants. Contact the research team at rrnair@houstonmethodist.org for enrollment information.

Where is the NCT06736951 trial being conducted?

This trial is being conducted at Baytown, United States, Houston, United States, Houston, United States, Houston, United States and 1 additional location.

Who is sponsoring the NCT06736951 clinical trial?

NCT06736951 is sponsored by Farhaan S. Vahidy. The principal investigator is Farhaan Vahidy, PhD at The Methodist Hospital Research Institute. The trial plans to enroll 10,890 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology